PCN136 - A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN CANADA

Value in Health ◽

10.1016/j.jval.2018.09.219 ◽

2018 ◽

Vol 21 ◽

pp. S37 ◽

Author(s):

K. Lakhdari ◽

K.C. Young ◽

O. Holdgate ◽

J. Doan

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Effectiveness Analysis

Download Full-text

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma

Frontiers in Pharmacology ◽

10.3389/fphar.2020.00619 ◽

2020 ◽

Vol 11 ◽

Author(s):

Peiyao Lu ◽

Weiting Liang ◽

Jiahao Li ◽

Yanming Hong ◽

Zhuojia Chen ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Effectiveness Analysis

Download Full-text

A Cost‐Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First‐Line Intermediate‐ to Poor‐Risk Advanced Renal Cell Carcinoma

The Oncologist ◽

10.1634/theoncologist.2018-0656 ◽

2019 ◽

Vol 24 (3) ◽

pp. 366-371 ◽

Author(s):

Daniel Reinhorn ◽

Michal Sarfaty ◽

Moshe Leshno ◽

Assaf Moore ◽

Victoria Neiman ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Poor Risk ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China

Clinical Drug Investigation ◽

10.1007/s40261-019-00820-6 ◽

2019 ◽

Vol 39 (10) ◽

pp. 931-938 ◽

Author(s):

Jun Chen ◽

Gaoyun Hu ◽

Zhuo Chen ◽

Xiaomin Wan ◽

Chongqing Tan ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Effectiveness Analysis

Download Full-text

A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2021.01.009 ◽

2021 ◽

Author(s):

Rebecca Shay ◽

Andrew Nicklawsky ◽

Dexiang Gao ◽

Elaine T. Lam

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma

American Journal of Clinical Oncology ◽

10.1097/coc.0000000000000884 ◽

2022 ◽

Vol Publish Ahead of Print ◽

Author(s):

Alan Chan ◽

Carolyn Dang ◽

Jessica Wisniewski ◽

Xiuhua Weng ◽

Edward Hynson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Sorafenib versus Best Supportive Care in Advanced Renal Cell Carcinoma in Spain

SSRN Electronic Journal ◽

10.2139/ssrn.944301 ◽

2006 ◽

Author(s):

Pablo Maroto ◽

Humberto Villavicencio ◽

Carme Pinol ◽

Leyre Urruticoechea

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Supportive Care ◽

Cell Carcinoma ◽

Best Supportive Care ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Effectiveness Analysis

Download Full-text

A cost-effectiveness analysis of Nivolumab and Ipilimumab versus Sunitinib in first line intermediate-poor risk advanced Renal Cell Carcinoma

European Urology Supplements ◽

10.1016/s1569-9056(18)33792-8 ◽

2018 ◽

Vol 17 (14) ◽

pp. e2941

Author(s):

D. Reinhorn ◽

M. Sarfaty ◽

M. Leshno ◽

V. Neiman ◽

E. Rosenbaum ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Poor Risk ◽

Effectiveness Analysis

Download Full-text

PCN70 Cost Effectiveness Analysis Based on Progression Free Survival (PFS) of Pazopanib Versus Sunitinib for the Treatment of Advanced Renal Cell Carcinoma (ARCC) in the Mexican Context

Value in Health ◽

10.1016/j.jval.2012.03.1187 ◽

2012 ◽

Vol 15 (4) ◽

pp. A220 ◽

Author(s):

P. Anaya ◽

T.E. Delea ◽

P. Pichardo ◽

J.R. Diaz

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Progression Free Survival ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Free Survival ◽

Effectiveness Analysis

Download Full-text

A Cost-Effectiveness Analysis of Axitinib and Sorafenib for 2nd Line Treatment of Advanced Renal Cell Carcinoma After Failure of Cytokines in the United States

Value in Health ◽

10.1016/j.jval.2013.08.500 ◽

2013 ◽

Vol 16 (7) ◽

pp. A410 ◽

Author(s):

I.O. Stillman ◽

A. Ambavane ◽

P. Cislo

Keyword(s):

United States ◽

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

The United States ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

Effectiveness Analysis

Download Full-text

PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE

Value in Health ◽

10.1016/j.jval.2019.09.410 ◽

2019 ◽

Vol 22 ◽

pp. S477

Author(s):

S. Branchoux ◽

S. Négrier ◽

C. de Peretti ◽

B. Malcolm ◽

J. May ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text